A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC-LIVIGNO-1

This study is being done to answer the following question: Can we determine the optimal (safe & effective) dose of livmoniplimab for patients? Also to determine if livmoniplimab combined with budigalimab is safe and effective at treating locally advanced or metastatic Child-Pugh A hepatocellular carcinoma (mHCC).